कृपया अन्य खोज का प्रयास करें
Voluntis S.A. develops digital therapeutic solutions for diabetes, oncology, and other therapeutic areas in France and the United States. It offers Insulia, a prescription medical device that provides automated basal insulin dose recommendations and coaching messages for people with type 2 diabetes; and Diabeo, a digital solution for type 1 and type 2 patients treated on a basal-bolus insulin regimen, which suggests insulin dosage, through algorithmic calculations that are specific to the patient and based on their particular doses. The company provides Oleena, a first FDA class II software-as-a-medical device for cancer indications; AstraZeneca, an e-Cediranib Olaparib application designed for patient self-reporting and management of hypertension and diarrhea; Theraxium Oncology, a cornerstone software platform for all digital therapeutics of cancer treatment, as well as coagulation and hemophilia solutions. Voluntis S.A. has a collaboration agreement with Bristol-Myers Squibb Company to co-develop digital Therapeutics for Oncology. Voluntis S.A. was founded in 2001 and is based in Suresnes, France. Voluntis S.A. operates as a subsidiary of AptarGroup, Inc.
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है